Autopsy report · NCT03229382

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

“Very slow recruitment due to lack of relapse in the observed group of patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months before it started.
• Ran for about 1 year 9 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Polish Lymphoma Research Group

Sponsor type

University, hospital or other

Conditions

Mantle Cell Lymphoma

Interventions

Obinutuzumab

Participants

1

Sites

1

Countries

Poland

Trials that died the same way

• The Clinical and Laboratory Phenotypes of Severe Asthma Patients in Clalit Health Services Haifa
  “Slow recruitment of patients” (82% match in meaning)
• TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors
  “slow recruitment (only 8 patients recruited and treated until 12/2012)” (80% match in meaning)
• Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat")
  “difficulties of recruitment, high number of patients lost to follow-up” (78% match in meaning)
• Propofol and Dexmedetomidin vs Midazolam Intraoperative Sedation and POCD
  “Too long recruitment period due to small number of patients” (77% match in meaning)
• Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
  “study was stopped after enrolment of about 200 patients for slow recruitment” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.